Top 2 Health Care Stocks That May Crash This Quarter
Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
Gilead to acquire Arcellx for $7.8 billion
Why Is Arcellx Stock Surging Today?